Familial short stature (FSS) is a condition where a child’s height falls below the 3rd percentile for their age and sex, but the short stature is inherited from one or both parents rather than caused by a hormone deficiency or medical problem. These children are small because their parents are small. They grow at a normal, steady rate, hit puberty on time, and reach an adult height that’s short but proportional to their family’s genetic pattern.
FSS is one of the two most common reasons a child ends up shorter than their peers, the other being constitutional growth delay (where a child is a “late bloomer” who catches up later). Understanding the difference matters because the causes, the expected outcomes, and the approach to each are quite different.
How Familial Short Stature Is Defined
Short stature in general means a height more than 2 standard deviations below the average for a child’s age, sex, and population. Statistically, that’s the 2.3rd percentile, though most clinical guidelines round down to the 3rd percentile as a practical cutoff. Children with FSS typically fall between 2 and 3 standard deviations below the mean.
What separates FSS from other causes of short stature is context. One or both parents are also short, and the child’s height tracks consistently along their own growth curve rather than falling away from it over time. The child isn’t failing to grow. They’re growing exactly as their genetics dictate.
Growth Patterns That Signal FSS
The hallmark of familial short stature is a normal growth velocity. During childhood, a healthy growth rate is roughly 5 to 5.5 centimeters per year. Toddlers grow faster, around 6 to 7 centimeters annually, and adolescents during their growth spurt can add 8 to 12 centimeters (girls) or 10 to 14 centimeters (boys) per year. A child with FSS hits all of these benchmarks. They’re just doing it from a lower starting point on the growth chart.
This is the key distinction from constitutional growth delay, where growth velocity actually slows down during childhood before catching up later during a delayed puberty. In FSS, puberty arrives at the expected age, the growth spurt happens on schedule, and the child reaches their final adult height without a prolonged period of waiting. That final height is short, but it’s appropriate for their family.
Bone Age and What It Reveals
One of the most useful tools for distinguishing FSS from other growth conditions is a bone age X-ray, typically taken of the left hand and wrist. In children with familial short stature, bone age matches chronological age. A 10-year-old with FSS has bones that look like a 10-year-old’s.
This is different from constitutional growth delay, where bone age lags behind. A 10-year-old with constitutional delay might have a bone age of 8, meaning they have extra growing time ahead. Children with FSS don’t have that cushion. Their bones are maturing on schedule, which is why their adult height will be short rather than catching up later.
Predicting Adult Height With Mid-Parental Height
Doctors use a calculation called mid-parental height to estimate a child’s genetic height potential. The formula averages both parents’ heights and then adjusts for sex: add 6.5 centimeters when predicting a son’s height, or subtract 6.5 centimeters for a daughter’s. The child’s final adult height is expected to land within about 9 centimeters of that number for girls and 10 centimeters for boys.
In familial short stature, the child’s projected adult height falls within this target range. That alignment is actually one of the strongest clues that the short stature is familial. If a child’s height is tracking well below even their mid-parental target, something else may be going on, and further workup is warranted. The Growth Hormone Research Society and major pediatric endocrine societies recommend using these cutoffs when evaluating children with unexplained short stature.
How FSS Is Diagnosed
Familial short stature is largely a diagnosis of exclusion, meaning doctors confirm it by ruling out other causes first. The evaluation typically includes blood work to check thyroid function, markers of growth hormone activity (IGF-1 and IGFBP-3), a complete blood count, a metabolic panel, and screening for celiac disease. Inflammatory markers may also be checked to rule out chronic conditions that can silently suppress growth. For girls, chromosome testing may be considered to rule out Turner syndrome, which can look similar on a growth chart.
If all of these come back normal, the growth velocity is steady, bone age matches chronological age, and at least one parent is short, the picture points clearly to FSS. No single test confirms it. The diagnosis comes from the whole pattern fitting together.
The Genetic Side of Inherited Short Stature
Height is influenced by hundreds of genes, and in most families with FSS, the short stature is simply the result of many common genetic variants adding up. But in some cases, a single gene plays an outsized role. Mutations in the SHOX gene, which helps regulate bone growth, are one of the better-understood genetic causes. These mutations occur in roughly 1 in 1,000 to 1 in 2,000 people and can cause short stature with or without subtle limb abnormalities.
SHOX mutations often run through families in a clear inheritance pattern. In one documented case, an 8-year-old girl stood at 105 centimeters (more than 4 standard deviations below average), and testing revealed the same SHOX mutation in her father, grandfather, uncle, and sister. Cases like this highlight why genetic testing can be valuable even when short stature “runs in the family.” Identifying a specific mutation can sometimes open the door to treatment options that wouldn’t otherwise be considered.
Treatment Options and Realistic Expectations
Because familial short stature isn’t caused by a hormone deficiency, growth hormone therapy isn’t a standard treatment for it. However, in 2003, growth hormone was approved in the United States for a broader category called idiopathic short stature (ISS), which includes children with height at or below the 1.2 percentile whose workup shows no other treatable cause. Some children with FSS technically qualify under this umbrella.
The results of growth hormone treatment in non-deficient children are modest. On average, treated children gain about 4 centimeters (roughly 1.5 inches) of additional adult height compared to untreated children. That’s a meaningful but limited gain, and it requires years of daily injections. The decision to treat involves weighing that modest benefit against the cost, the commitment, and the child’s own feelings about treatment. For children with identified SHOX gene mutations specifically, growth hormone therapy tends to be more clearly recommended and may produce better responses.
Emotional and Social Effects
Short stature affects more than growth charts. Research consistently shows that children who remain below the 2-standard-deviation threshold experience more internalizing problems (anxiety, withdrawal, low mood) compared to peers who reach normal height. Parents report these difficulties too, and condition-specific quality of life, meaning how kids feel about their height in daily situations, is lower in children who stay short.
Interestingly, children who received growth hormone treatment reported better overall quality of life than untreated children, even when controlling for whether they actually reached normal height. This suggests the experience of being actively treated may itself provide some psychological benefit, perhaps through a sense of agency or hope. On the other hand, untreated children who remained short developed stronger coping skills over time, though they also held less positive beliefs about their height.
For families navigating FSS, these findings point to something important: the emotional experience of being short matters, and addressing it directly, whether through treatment, counseling, or simply open conversation, can make a real difference in how a child moves through childhood.